JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB97812

Anti-VCIP 135 antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Polyclonal VCIP 135 antibody. Suitable for WB, IHC-P and reacts with Mouse, Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human VCPIP1 aa 950 to C-terminus.

View Alternative Names

KIAA1850, VCIP135, VCPIP1, Deubiquitinating protein VCPIP1, Valosin-containing protein p97/p47 complex-interacting protein 1, Valosin-containing protein p97/p47 complex-interacting protein p135, VCP/p47 complex-interacting 135-kDa protein

4 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VCIP 135 antibody (AB97812)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VCIP 135 antibody (AB97812)

Immunohistochemical analysis of paraffin-embedded SW480 xenograft, using ab97812 at 1/100 dilution.

Western blot - Anti-VCIP 135 antibody (AB97812)
  • WB

Unknown

Western blot - Anti-VCIP 135 antibody (AB97812)

7.5% SDS Page

All lanes:

Western blot - Anti-VCIP 135 antibody (ab97812) at 1/5000 dilution

All lanes:

H1299 whole cells lysate at 30 µg

Predicted band size: 134 kDa

false

Western blot - Anti-VCIP 135 antibody (AB97812)
  • WB

Supplier Data

Western blot - Anti-VCIP 135 antibody (AB97812)

Samples were separated by 5% SDS-PAGE.

All lanes:

Western blot - Anti-VCIP 135 antibody (ab97812) at 1/1000 dilution

Lane 1:

Wild-type (WT) HeLa cell extracts at 30 µg

Lane 2:

VCPIP1 knockout (KO) HeLa cell extracts at 30 µg

Secondary

All lanes:

HRP-conjugated anti-rabbit IgG antibody

Predicted band size: 134 kDa

false

Western blot - Anti-VCIP 135 antibody (AB97812)
  • WB

Supplier Data

Western blot - Anti-VCIP 135 antibody (AB97812)

Samples were separated by 5% SDS PAGE.

All lanes:

Western blot - Anti-VCIP 135 antibody (ab97812) at 1/1000 dilution

All lanes:

Mouse brain tissue lysate at 50 µg

Predicted band size: 135 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Human

Applications

IHC-P, WB

applications

Immunogen

Recombinant Fragment Protein within Human VCPIP1 aa 950 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

Q96JH7

style
left-column

Complementary Products

Primary Antibodies

AB234847

Anti-TRIM13 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRIM13 antibody (AB234847)

  • 0
  • 0
Primary Antibodies

AB167059

Anti-USP19 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-USP19 antibody (AB167059)

  • 0
  • 0
Primary Antibodies

AB96551

Anti-MAP4K5 antibody

Immunocytochemistry/ Immunofluorescence - Anti-MAP4K5 antibody (AB96551)

  • 4
  • 1
Primary Antibodies

AB111697

Anti-ZNF587 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ZNF587 antibody (AB111697)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/1000", "IHCP-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

VCIP135 also known as VCP-interacting protein p135 plays an important role in the process of membrane fusion. This protein has a mass of approximately 135 kDa and is found mainly in the cytosol and nucleus of cells. It directly interacts with valosin-containing protein (VCP) which is important for various cellular functions. The expression of VCIP135 has been noted across multiple tissues highlighting its diverse involvement in cellular activities.
Biological function summary

VCIP135 facilitates endoplasmic reticulum and Golgi membrane fusion by interacting within the VCP complex. In this mechanism it regulates the dynamics of vesicle trafficking and processing influencing the maintenance of cellular homeostasis. By ensuring proper fusion and reassembly of vesicular membranes VCIP135 impacts how well a cell manages its transport and secretory pathways. Its function in coordinating membrane systems confirms its integral role in cell integrity.

Pathways

VCIP135 significantly contributes to the ER-associated degradation (ERAD) and protein ubiquitination pathways. During these processes VCIP135 collaborates closely with proteins such as ubiquitin and VCP to direct the proper destruction of misfolded proteins. This cooperation ensures that the cell adequately manages protein quality control preventing the build-up of harmful nonfunctional proteins. These processes are essential in safeguarding cellular health and consistent workflow of molecular machinery.

Improper function of VCIP135 links to neurodegenerative disorders such as Parkinson's disease and inclusion body myopathy. These conditions often involve protein aggregation due to deficient ubiquitin-proteasome system activity a pathway in which VCIP135 retains functionality through its interaction with VCP. Aberrations in this pathway lead to toxic protein build-up which in turn impacts neuron and muscle cell survival. Understanding VCIP135's role in these diseases aids in developing therapeutic strategies toward modulation of its activity.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Deubiquitinating enzyme involved in DNA repair and reassembly of the Golgi apparatus and the endoplasmic reticulum following mitosis (PubMed : 32649882). Necessary for VCP-mediated reassembly of Golgi stacks after mitosis (By similarity). Plays a role in VCP-mediated formation of transitional endoplasmic reticulum (tER) (By similarity). Mediates dissociation of the ternary complex containing STX5A, NSFL1C and VCP (By similarity). Also involved in DNA repair following phosphorylation by ATM or ATR : acts by catalyzing deubiquitination of SPRTN, thereby promoting SPRTN recruitment to chromatin and subsequent proteolytic cleavage of covalent DNA-protein cross-links (DPCs) (PubMed : 32649882). Hydrolyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitin chains (PubMed : 23827681).. (Microbial infection) Regulates the duration of C.botulinum neurotoxin type A (BoNT/A) intoxication by catalyzing deubiquitination of Botulinum neurotoxin A light chain (LC), thereby preventing LC degradation by the proteasome, and accelerating botulinum neurotoxin intoxication in patients.
See full target information VCPIP1
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

eLife 8: PubMed31741433

2019

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC.

Applications

Unspecified application

Species

Unspecified reactive species

Hao Zeng,Johnny Castillo-Cabrera,Mika Manser,Bo Lu,Zinger Yang,Vaik Strande,Damien Begue,Raffaella Zamponi,Shumei Qiu,Frederic Sigoillot,Qiong Wang,Alicia Lindeman,John S Reece-Hoyes,Carsten Russ,Debora Bonenfant,Xiaomo Jiang,Youzhen Wang,Feng Cong
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com